We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?
Read MoreHide Full Article
Key Takeaways
Inspire's long-term case rests on a $10B-plus U.S. market with penetration still below 5%.
Coding, authorization delays and uneven Medicare payments cut second-quarter revenue by about $40M.
Inspire V lifted gross margin to 85.5%, while $320.7M in cash and no debt add financial flexibility.
Inspire Medical Systems, Inc. (INSP - Free Report) offers investors a difficult trade-off. Its underpenetrated obstructive sleep apnea market, improving margins and financial flexibility support the long-term case.
Near-term execution remains less certain. Coding changes, prior-authorization delays and inconsistent Medicare reimbursement continue to restrain procedure volumes, making patience more appropriate than an aggressive entry.
Inspire’s Market Opportunity Remains Large
Management estimates the U.S. opportunity at more than $10 billion, with market penetration below 5%. More than 140,000 patients have received Inspire therapy, while over 1,500 physicians perform implants.
That adoption base leaves substantial room for expansion if access improves. ResMed Inc. (RMD - Free Report) , a major provider of continuous positive airway pressure therapy, also serves the large sleep apnea market, underscoring both the demand opportunity and established competition.
Inspire ended the second quarter with $320.7 million in cash, cash equivalents and short-term investments. The company had no debt, limiting near-term balance-sheet pressure during the reimbursement disruption.
Operating cash flow reached $36.1 million in the first half of 2026, compared with cash use of $4 million a year earlier. This liquidity gives Inspire room to fund patient-access programs, commercial execution and research.
Inspire V Improves the Economic Model
Inspire V represented the large majority of second-quarter implants and helped lift gross margin to 85.5%, up 150 basis points year over year. Its integrated respiratory sensor simplifies the implant procedure.
CMS has proposed raising 2027 Medicare facility reimbursement by about 12% for hospital outpatient procedures and 15% for ambulatory surgery centers. Those increases could improve procedure economics, but final rates are expected in November 2026.
Image Source: Zacks Investment Research
INSP’s Growth Case Still Has Friction
Coding and reimbursement disruption, including the WISeR prior-authorization program in six Medicare pilot states, reduced second-quarter revenues by about $40 million. Management expects a $120-$130 million full-year revenue impact.
Two Medicare Administrative Contractors still require a reduced-services modifier, creating uneven surgeon payments. Eli Lilly and Company (LLY - Free Report) adds another variable because Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity, potentially affecting treatment sequencing.
Inspire’s Valuation Balances Risk and Opportunity
INSP trades at roughly 2.1X forward sales, below the sub-industry multiple of 5.1X and its five-year median of 7.1X. The discount recognizes the company’s weaker near-term growth visibility.
A durable re-rating likely requires improving U.S. procedure trends, more consistent reimbursement and evidence that patient-flow investments are converting demand into implants. Until then, the lower multiple alone does not remove execution risk.
INSP’s Scores Point to a Hold
The bottom line is that margin improvement, liquidity and a large addressable market support holding INSP, while reimbursement uncertainty limits the case for buying aggressively now.
The stock currently carries a Zacks Rank #3 (Hold). Its Growth Score of B and VGM Score of B recognize favorable growth characteristics, while its Value Score of C and Momentum Score of C indicate a more balanced setup. The scores support waiting for clearer operating momentum before taking a stronger view. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?
Key Takeaways
Inspire Medical Systems, Inc. (INSP - Free Report) offers investors a difficult trade-off. Its underpenetrated obstructive sleep apnea market, improving margins and financial flexibility support the long-term case.
Near-term execution remains less certain. Coding changes, prior-authorization delays and inconsistent Medicare reimbursement continue to restrain procedure volumes, making patience more appropriate than an aggressive entry.
Inspire’s Market Opportunity Remains Large
Management estimates the U.S. opportunity at more than $10 billion, with market penetration below 5%. More than 140,000 patients have received Inspire therapy, while over 1,500 physicians perform implants.
That adoption base leaves substantial room for expansion if access improves. ResMed Inc. (RMD - Free Report) , a major provider of continuous positive airway pressure therapy, also serves the large sleep apnea market, underscoring both the demand opportunity and established competition.
Inspire Medical Systems, Inc. Price and Consensus
Inspire Medical Systems, Inc. price-consensus-chart | Inspire Medical Systems, Inc. Quote
INSP’s Balance Sheet Supports Patience
Inspire ended the second quarter with $320.7 million in cash, cash equivalents and short-term investments. The company had no debt, limiting near-term balance-sheet pressure during the reimbursement disruption.
Operating cash flow reached $36.1 million in the first half of 2026, compared with cash use of $4 million a year earlier. This liquidity gives Inspire room to fund patient-access programs, commercial execution and research.
Inspire V Improves the Economic Model
Inspire V represented the large majority of second-quarter implants and helped lift gross margin to 85.5%, up 150 basis points year over year. Its integrated respiratory sensor simplifies the implant procedure.
CMS has proposed raising 2027 Medicare facility reimbursement by about 12% for hospital outpatient procedures and 15% for ambulatory surgery centers. Those increases could improve procedure economics, but final rates are expected in November 2026.
Image Source: Zacks Investment Research
INSP’s Growth Case Still Has Friction
Coding and reimbursement disruption, including the WISeR prior-authorization program in six Medicare pilot states, reduced second-quarter revenues by about $40 million. Management expects a $120-$130 million full-year revenue impact.
Two Medicare Administrative Contractors still require a reduced-services modifier, creating uneven surgeon payments. Eli Lilly and Company (LLY - Free Report) adds another variable because Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity, potentially affecting treatment sequencing.
Inspire’s Valuation Balances Risk and Opportunity
INSP trades at roughly 2.1X forward sales, below the sub-industry multiple of 5.1X and its five-year median of 7.1X. The discount recognizes the company’s weaker near-term growth visibility.
A durable re-rating likely requires improving U.S. procedure trends, more consistent reimbursement and evidence that patient-flow investments are converting demand into implants. Until then, the lower multiple alone does not remove execution risk.
INSP’s Scores Point to a Hold
The bottom line is that margin improvement, liquidity and a large addressable market support holding INSP, while reimbursement uncertainty limits the case for buying aggressively now.
The stock currently carries a Zacks Rank #3 (Hold). Its Growth Score of B and VGM Score of B recognize favorable growth characteristics, while its Value Score of C and Momentum Score of C indicate a more balanced setup. The scores support waiting for clearer operating momentum before taking a stronger view. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.